Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Recent literature has both suggested and questioned MTH1 as a novel cancer target. BAY-707 was just published as a target validation small molecule probe for assessing the effects of pharmacological inhibition of MTH1 on tumor cell survival, both in vitro and in vivo. (1) In this report, we describe the medicinal chemistry program creating BAY-707, where fragment-based methods were used to develop a series of highly potent and selective MTH1 inhibitors. Using structure-based drug design and rational medicinal chemistry approaches, the potency was increased over 10,000 times from the fragment starting point while maintaining high ligand efficiency and drug-like properties.

Original publication

DOI

10.1021/acs.jmedchem.7b01884

Type

Journal article

Journal

J Med Chem

Publication Date

22/03/2018

Volume

61

Pages

2533 - 2551

Keywords

Animals, Antineoplastic Agents, Caco-2 Cells, Cell Membrane Permeability, DNA Repair Enzymes, Drug Design, Drug Discovery, Drug Evaluation, Preclinical, Hepatocytes, Humans, Mice, Microsomes, Liver, Models, Molecular, Molecular Structure, Morpholines, Phosphoric Monoester Hydrolases, Rats, Rats, Wistar, Structure-Activity Relationship